Sartorius Stedim Biotech (SDMHF) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the presentation of Sartorius and Sartorius' TED in biotechs on the preliminary results 2025. Please note that the call is being recorded and streamed on Sartorius' website. Your participation in this implies you consent with this. A replay will be available shortly after the call. Please note that management comments during this call will include forward-looking statements that involve risks and uncertainty for discussion of risk factors. I encourage you to review the safe harbor statement contained in today's press release and presentation. With that, I'm pleased to hand over to Michael Forster, CEO of Sartorius. Michael, please go ahead. Thank you very much, Petra, and a warm welcome also from my side. And thank you all for joining us today for our preliminary full year 2025 results. Before we begin, I would like to sincerely thank all of our colleagues across Sartorius for their commitment and dedication over the past year. Their passion, professionalism, and strong focus on execution are clearly reflected in our results we are presenting today. I would also like to personally thank everyone who has made it such a smooth and rewarding experience for me to step into my role as a CEO, and particular thanks as well to my colleagues here, Alexandra, Renee, and Florian from the executive team, It's been really a great journey up to now, fantastic work on the strategy, and great things to come. And I don't want to miss out as well on saying thank you to the team here from investor relations, communications, and finance, because I think the workload over the last couple of weeks and days has been tremendous in order to get us all prepared and get our reporting in place. Thank you all for that. Now, let me briefly summarize key messages that we would like to s...